NEWS
NeoPL® human platelet lysate is a xeno-free, growth-factor-rich replacement for FBS, made from pathogen-tested donor platelets collected at FDA-licensed US blood centers.
5% vs 20%NeoPL® at 5% outgrew 20% FBS
>99.3%MSC marker expression maintained
+55%more live cells with NeoPL®-Boost vs another hPL
Faster growth at a quarter of the concentration
MSC identity preserved
| Supplement | CD105 | CD90 | CD73 | CD44 | CD29 | CD13 |
|---|---|---|---|---|---|---|
| NeoPL®-Apex | 99.37% | 99.97% | 99.80% | 99.86% | 99.97% | 99.88% |
| NeoPL®-Nova | 99.82% | 99.97% | 99.89% | 99.82% | 99.99% | 99.97% |
NeoPL®-Boost vs a standard hPL
| 120 h culture, 0.2 × 10⁶ cells seeded | 5% NeoPL®-Boost | 5% other hPL |
|---|---|---|
| Live cells (×10⁶) | 1.16 | 0.75 |
| Doubling time (h) | 47.1 | 62.6 |
| Viability | 96% | 92.5% |
| Cumulative PDL | 5.83 | 3.77 |
Formats: NeoPL®-Boost, -Nova (heparin-free, fibrinogen-depleted) and -Apex (fibrinogen-depleted), in research and GMP grade, 100 mL and 500 mL.
Shop NeoPL® → Request a quote or sample →
Shop NeoPL® → Request a quote or sample →
AICON-BIO internal data. Results may vary with cell source and culture conditions.